Analyst Research

Report Title Price
Provider: Plunkett Research, Ltd.
$99.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca announces results from phase III monotherapy study of lesinurad in gout patients


Thursday, 12 Dec 2013 07:00pm EST 

AstraZeneca PLC:Says top-line results from LIGHT show that patients treated with lesinurad monotherapy were more likely to experience serum creatinine elevations and renal adverse events, including serious events, compared to patients on placebo.Says other commonly reported adverse events in patients treated with lesinurad monotherapy were diarrhoea, nausea and constipation.Says the Phase III LIGHT study investigated the potential of lesinurad as a monotherapy in the small population of gout patients who are intolerant to, or otherwise cannot take, one or both xanthine oxidase inhibitors allopurinol and febuxostat. 

Company Quote

4425.5
35.5 +0.81%
11:14am EDT